15.25

0.28% 0.043

After Hours: 15.90 0.65 +4.26%

Polyrizon Ltd (PLRZ)

Overview News Price History Discussions Forecast

Polyrizon Ltd stock is traded at $15.25, with a volume of 66,261. It is up +0.28% in the last 24 hours and up +17.40% over the past month. Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.

Previous Close:

$15.21

Open:

$14.745

24h Volume:

66,261

Relative Volume:

1.44

Market Cap:

$31.78M

Revenue:

Net Income/Loss:

$-3.34M

P/E Ratio:

-5.6492

EPS:

-2.6995

Net Cash Flow:

$-10.54M

1W Performance:

+21.81%

1M Performance:

+17.40%

6M Performance:

+23.23%

1Y Performance:

+265.39%

1-Day Range:

$14.25

$15.91

1-Week Range:

$12.00

$15.91

52-Week Range:

$2.88

$18.20

Polyrizon Ltd Stock (PLRZ) Company Profile

Name

Polyrizon Ltd

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-07-01

Latest SEC Filings

PLRZ's Discussions on Twitter

Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRZ Polyrizon Ltd	15.25	31.69M	0	-3.34M	-10.54M	-2.6995
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Polyrizon Ltd Stock (PLRZ) Latest News

Jul 02, 2026

Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks

Jul 02, 2026

Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan

Jul 02, 2026

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance

Jul 02, 2026

Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com

Jul 02, 2026

Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria

Jul 02, 2026

Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com India

Jul 02, 2026

Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative

Jul 02, 2026

Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan

Jul 02, 2026

Polyrizon Advances on Test Results - Baystreet.ca

Jul 02, 2026

Jun 29, 2026

Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks

Jun 29, 2026

[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan

Jun 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 29, 2026

Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com

Jun 29, 2026

Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Canada

Jun 29, 2026

Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative

Jun 29, 2026

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times

Jun 29, 2026

Polyrizon clears review to start first NASARIX human allergy trial - Stock Titan

Jun 29, 2026

Jun 27, 2026

Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView

Jun 27, 2026

Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView

Jun 27, 2026

Jun 25, 2026